Biomedtracker

Report Library

Diabetes CVOTs Primary Care KOL Interview

December 01, 2016

Biomedtracker and Datamonitor Healthcare interviewed a primary care physician (PCP) in the US to gauge the impact of Jardiance's EMPA-REG and Victoza's LEADER cardiovascular outcomes trials (CVOT) in that important segment of the Type 2 diabetes market. The PCP discussed:

What type of patients and lines of therapy the drugs would be used in for Type 2 diabetes
Use of the particular drugs versus the overall SGLT-2 inhibitor and GLP-1 agonist classes and view on semaglutide
Role of possible differing mechanisms for the CV benefit
Impact of label changes
Projections on use
Implications for DPP-IV inhibitors
Whether cardiologists would have a role in uptake
Insurance coverage and impact of pay-for-performance
Usage in diabetic nephropathy

The PDUFA date for a CV indication for Jardiance is expected December 2, 2016, but even if the initial decision is negative, it is likely the drug will gain the indication once it is confirmed by another in the class. This interview was done in conjunction with our Diabetes CVOTs Survey.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered:

Acute Coronary Syndrome (ACS)
Acute Decompensated Heart Failure - Reduced Ejection Fraction (Acute HFrEF)
Atherosclerosis
Cardiovascular Disease
Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Coronary Artery Disease
Diabetes Mellitus, Type II
Diabetic Nephropathy
Ischemic Stroke

Additional Resources: